Research
Hormonal
46 to 75% of participants receiving orforglipron achieved a weight reduction of at least 10% by week 36.
A significant proportion of adults with obesity may achieve clinically meaningful weight loss with orforglipron.
StrongSupportsmedium confidence
A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo.
Why this rating
Based on the phase 2 randomized, double-blind trial design.
Source
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton et al. · New England Journal of Medicine · 2023
DOI 10.1056/nejmoa2302392
rct · n=272Cited 412×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Daily oral orforglipron was associated with a mean weight reduction ranging from -8.6% to -12.6% at week 26 and -9.4% to -14.7% at week 36 in participants receiving the drug.Strong
- The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →